Cognitive Decline and Dementia

Claassen, Jurgen A.H.R.

doi:10.1161/hypertensionaha.114.04706

Cited by 11 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Many cases of VaD start with slight early warning signs: slowness of though, difficulty with planning trouble with attention, and concentration mood or behavioral changes. Left untreated, the symptoms may continue to get worse (6). Currently, no available treatments can repair the damage of VaD once it happened (7).…”

Section: Introductionmentioning

confidence: 99%

Anti-Inflammatory and Neuroprotective Effects of Co-UltraPEALut in a Mouse Model of Vascular Dementia

et al. 2017

View full text Add to dashboard Cite

Vascular dementia (VaD), the second most common cause of cognitive impairment in the population, is a disease that results from reduction in regional cerebral blood flow and involves oxidative stress and inflammation. Co-ultramicronized PEALut (co-ultra PEALut) is a new compound with beneficial effects, which include anti-inflammatory and antioxidant properties. Recently, co-ultraPEALut has been shown to exhibit neuroprotective effects in models of Parkinson’s disease, cerebral ischemia and Alzheimer’s disease. However, its effects on VaD remain unknown. Therefore, the purpose of the present study was to highlight the potential neuroprotective actions of co-ultraPEALut containing N-palmitoylethanolamine (PEA) and the antioxidant flavonoid luteolin (Lut) (10:1 by mass) in a mouse model of VaD induced by bilateral carotid arteries occlusion. At 24 h after VaD induction, mice were orally treated with 1 mg/kg co-ultraPEALut daily for 15 days. On the 15th day, brain tissues were processed for histological, immunohistochemical, Western blot, and immunofluorescent analysis. Our results clearly demonstrate that co-ultraPEALut improved learning, memory ability, locomotor activity, and the reciprocal social interaction. In addition, the mice subjected to VaD and treated with the co-ultraPEALut showed a reorganization of CA1 and CA3 regions of the hippocampus and restored the number of hippocampal neurons as evidenced by NeuN expression, a specific marker of neurons. Furthermore following carotid arteries ligation, mice treated with co-ultraPEALut showed a modification of proinflammatory, proapoptotic proteins and of oxidative stress as evidenced by the expression of IκB-α, NF-κB p65, Bax, Bcl-2, inducible nitric oxide synthase, and cyclooxygenase-2. In order, co-ultraPEALut treatment restored VaD-induced loss of brain-derived neurotrophic factor and neurotrophins 3 (NT-3) expression in mice. These results confirmed that the neuroprotective effects of co-ultraPEALut were associated with its anti-inflammatory and antioxidant properties.

show abstract

Section: Introductionmentioning

confidence: 99%

Anti-Inflammatory and Neuroprotective Effects of Co-UltraPEALut in a Mouse Model of Vascular Dementia

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Alzheimer’s disease is defined clinically by causing dementia and corresponds to 50–60% of all dementias, being the most prevalent (Alameda et al, 2012; Claassen, 2015). No curative treatment is currently available and the disease generates high healthcare, social, and family costs (Leon-Salas and Martínez-Martín, 2010).…”

Section: Introductionmentioning

confidence: 99%

Canine-Assisted Therapy and Quality of Life in People With Alzheimer-Type Dementia: Pilot Study

et al. 2019

View full text Add to dashboard Cite

Background With the aim of improving the quality of life of people with Alzheimer’s disease, primarily as regards behavioral and psychological symptoms, we implemented canine-assisted therapy in a group of people with this disease. Methods We conducted a quasi-experimental study, with a simple pre-post case series design. Participants comprised 10 Alzheimer’s day care center users presenting severe or very severe cognitive decline. The measurement instrument employed was the Quality of Life in Late-Stage Dementia (QUALID) scale. Results By the end of the therapy, 100% of participants showed an improvement in physical, behavioral, and psychological aspects. The total scores of the QUALID scale for the three different evaluation times (before the therapy and 6 and 12 months after starting) after the canine-assisted therapy intervention were smaller and less dispersed. The total score for the QUALID scale decreased significantly ( p < 0.05) at 6 and 12 months after starting therapy. An analysis by item revealed that the scores of all of them fell during the course of the therapy. Discussion Our study provides evidence of the significant benefits of canine-assisted therapy for quality of life in people with Alzheimer’s disease.

show abstract

“…Todavia, outros estudos apontam no sentido contrário, sublinhado que as QSM não predizem a futura progressão para demência (Silva et al, 2014), mas relacionam-se com a idade, a depressão, a ansiedade, o género feminino, a baixa escolaridade e a personalidade (Açikgöz et al, 2014;Blackburn et al, 2014;Mendes et al, 2008;Sousa, Pereira, & Costa, 2015a). Outros fatores de risco estão também associados ao desenvolvimento da demência, nomeadamente, a hipertensão, a diabetes (como a Hemoglobina glicosilada (HbA1c)), o colesterol e a obesidade (Claassen, 2015;Gao, Matthews, Sargeant, Brayne, & MRC FAS, 2008;Roriz-Filho et al, 2009). Todavia, pessoas adultas com QSM e elevados valores da HbA1c podem não ter nenhuma lesão cerebral associada (Exalto, van der Flier, Scheltens, Vrenken, & Biessels, 2014).…”

unclassified

As queixas subjetivas de memória num cuidado de saúde primário: Um estudo follow up

Sousa

Pereira

Costa

et al. 2017

Psychol. Community Health

View full text Add to dashboard Cite

ResumoObjetivo: As queixas subjetivas de memória (QSM) são um fator clínico relevante e uma das principais queixas feitas aos médicos de família por adultos e adultos idosos. Houve ainda um aumento da sintomatologia depressiva e ansiógena, dos valores da Hemoglobina glicosilada (HbA1c) e do número de medicamentos consumidos, com particular ênfase nos anti hipertensores. Conclusão: As QSM deverão ser objeto de preocupação e vigilância do médico de família, uma vez que podem representar um sintoma relevante para a identificação precoce de um processo demencial.Palavras-Chave: cuidados de saúde primários, pessoas adultas, pessoas idosas, queixas subjetivas de memória, depressão, ansiedade AbstractObjective: The subjective memory complaints (QSM) are an important clinical factor and a frequent problem in primary health care in adult and older people (Eichler et al., 2015). This study, carried out in a primary health care of the Central Region of Portugal, aimed to characterize the QSM according to sociodemographic, clinical, cognitive, emotional and quality of life variables. Methods: This longitudinal study at two time points aims to explore the process of the QSM for 18 months and which factors are associated with. It was conducted with a sample of 19 adults and older adults aged between 55 to 81 years (79.2% female). The data was collected by semi-structured interviews and whenever possible the medical records were consulted. It was used as measuring instruments the Portuguese version of the Mini Mental State Examination (MMSE), the Montreal Cognitive Assessment (MoCA), the Memory Complaint Scale (EQM), the Geriatric Depression Scale (GDS), the Anxiety Inventory Geriatrics (GAI) or the World Health Organization Quality of Life Assessment (WHOQOL-Bref) and a sociodemographic clinical questionnaire developed for this purpose. Results: In the second assessment moment all participants had QSM, which are significantly more influenced by age. It was also observed an increase in depressive symptoms and anxiety, the amounts of glycosylated hemoglobin (HbA1c) and the number of medications, with particular emphasis on anti-hypertensives. Conclusion:The QSM should be a matter of concern and vigilance from the family doctor, as this may be an important symptom for the early identification of individuals at higher risk for developing a dementing process.

show abstract

Cognitive Decline and Dementia

Cited by 11 publications

References 10 publications

Anti-Inflammatory and Neuroprotective Effects of Co-UltraPEALut in a Mouse Model of Vascular Dementia

Anti-Inflammatory and Neuroprotective Effects of Co-UltraPEALut in a Mouse Model of Vascular Dementia

Canine-Assisted Therapy and Quality of Life in People With Alzheimer-Type Dementia: Pilot Study

As queixas subjetivas de memória num cuidado de saúde primário: Um estudo follow up

Contact Info

Product

Resources

About